Trabectedin, a drug acting on both cancer cells and the tumour microenvironment

M. D'Incalci, N. Badri, C. M. Galmarini, P. Allavena

Research output: Contribution to journalArticle

Abstract

Trabectedin is the first marine-derived anti-neoplastic drug approved for the treatment of advanced soft tissue sarcoma and, in combination with pegylated liposomal doxorubicin, for the treatment of patients with relapsed platinum-sensitive ovarian cancer. From the beginning of its development, trabectedin showed some peculiar properties that clearly distinguished it from other anti-cancer drugs. In this mini-review, we will outline the current state of knowledge regarding the mode of action of trabectedin, which appears to represent a new class of anti-neoplastic drugs acting both on cancer cells and on the tumour microenvironment.

Original languageEnglish
Pages (from-to)646-650
Number of pages5
JournalBritish Journal of Cancer
Volume111
Issue number4
DOIs
Publication statusPublished - Aug 12 2014

Fingerprint

trabectedin
Cellular Microenvironment
Tumor Microenvironment
Pharmaceutical Preparations
Neoplasms
Platinum
Sarcoma
Ovarian Neoplasms
Therapeutics

Keywords

  • macrophages
  • microenvironment
  • sarcoma
  • trabectedin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. / D'Incalci, M.; Badri, N.; Galmarini, C. M.; Allavena, P.

In: British Journal of Cancer, Vol. 111, No. 4, 12.08.2014, p. 646-650.

Research output: Contribution to journalArticle

@article{ff7bf081657b4ceaaefe005c5f8d139f,
title = "Trabectedin, a drug acting on both cancer cells and the tumour microenvironment",
abstract = "Trabectedin is the first marine-derived anti-neoplastic drug approved for the treatment of advanced soft tissue sarcoma and, in combination with pegylated liposomal doxorubicin, for the treatment of patients with relapsed platinum-sensitive ovarian cancer. From the beginning of its development, trabectedin showed some peculiar properties that clearly distinguished it from other anti-cancer drugs. In this mini-review, we will outline the current state of knowledge regarding the mode of action of trabectedin, which appears to represent a new class of anti-neoplastic drugs acting both on cancer cells and on the tumour microenvironment.",
keywords = "macrophages, microenvironment, sarcoma, trabectedin",
author = "M. D'Incalci and N. Badri and Galmarini, {C. M.} and P. Allavena",
year = "2014",
month = "8",
day = "12",
doi = "10.1038/bjc.2014.149",
language = "English",
volume = "111",
pages = "646--650",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Trabectedin, a drug acting on both cancer cells and the tumour microenvironment

AU - D'Incalci, M.

AU - Badri, N.

AU - Galmarini, C. M.

AU - Allavena, P.

PY - 2014/8/12

Y1 - 2014/8/12

N2 - Trabectedin is the first marine-derived anti-neoplastic drug approved for the treatment of advanced soft tissue sarcoma and, in combination with pegylated liposomal doxorubicin, for the treatment of patients with relapsed platinum-sensitive ovarian cancer. From the beginning of its development, trabectedin showed some peculiar properties that clearly distinguished it from other anti-cancer drugs. In this mini-review, we will outline the current state of knowledge regarding the mode of action of trabectedin, which appears to represent a new class of anti-neoplastic drugs acting both on cancer cells and on the tumour microenvironment.

AB - Trabectedin is the first marine-derived anti-neoplastic drug approved for the treatment of advanced soft tissue sarcoma and, in combination with pegylated liposomal doxorubicin, for the treatment of patients with relapsed platinum-sensitive ovarian cancer. From the beginning of its development, trabectedin showed some peculiar properties that clearly distinguished it from other anti-cancer drugs. In this mini-review, we will outline the current state of knowledge regarding the mode of action of trabectedin, which appears to represent a new class of anti-neoplastic drugs acting both on cancer cells and on the tumour microenvironment.

KW - macrophages

KW - microenvironment

KW - sarcoma

KW - trabectedin

UR - http://www.scopus.com/inward/record.url?scp=84906092874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906092874&partnerID=8YFLogxK

U2 - 10.1038/bjc.2014.149

DO - 10.1038/bjc.2014.149

M3 - Article

C2 - 24755886

AN - SCOPUS:84906092874

VL - 111

SP - 646

EP - 650

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 4

ER -